The proton-pump inhibitor test: Pros and cons
Available from: Poong-Lyul Rhee
- "The optimal duration of the PPI test has not been determined fully. In several studies, the duration has been about 7 days.34 Earlier pharmacological studies with therapeutic doses of PPI showed that this duration is long enough to reach a steady-state inhibition of acid secretion.25 "
[Show abstract] [Hide abstract]
ABSTRACT: Gastroesophageal reflux disease (GERD) is the most common cause of noncardiac chest pain (NCCP) and is present in up to 60% of patients with NCCP in Western countries. In Korea, after a reasonable cardiac evaluation, GERD is reported to underlie 41% of NCCP cases. Typical reflux symptoms are frequent in Korean patients suffering from NCCP. Therefore, a careful history of the predominant symptoms, including heartburn and acid regurgitation, is relatively indicative of the GERD diagnosis in Korea. In Korea, in contrast to Western countries, patients aged 40 years and over who have been diagnosed with NCCP but who are without alarming features should undergo endoscopy to exclude gastric cancer or peptic ulcers because of the higher prevalence of peptic ulcer disease and gastric cancers in the region. In a primary care setting, in the absence of any alarming symptoms, a symptomatic response to a trial of a proton pump inhibitor (PPI) is sufficient for the presumptive diagnosis of GERD. In addition, the optimal duration of a PPI test may be at least 2 weeks, as GERD symptoms tend to be less frequent or atypical in Korean patients than in patients from Western countries. In patients diagnosed with GERD-related NCCP, long-term therapy (more than 2 months) with double the standard dose of a PPI is required to alleviate symptoms. Esophageal dysmotility is relatively uncommon, and pain modulators seem to offer significant improvement of chest pain control in non-GERD-related NCCP. Most traditionally available tricyclics or heterocyclics have many undesirable effects. Therefore, newer drugs with fewer side effects (for example, the serotonin - norepinephrine reuptake inhibitors) may be needed.
Gut and liver 01/2012; 6(1):1-9. DOI:10.5009/gnl.2012.6.1.1 · 1.81 Impact Factor
FMC - Formación Médica Continuada en Atención Primaria 04/2006; 13(4). DOI:10.1016/S1134-2072(06)71311-1
Gastroentérologie Clinique et Biologique 05/2006; 30(5):742-749. DOI:10.1016/S0399-8320(06)73307-3 · 1.14 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.